Secondary Logo

Share this article on:

Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating

Nijim, Yousif MD; Awni, Youssef MD; Adawi, Amin MD; Bowirrat, Abdalla MD, PhD

Section Editor(s): Barzilay., Joshua

doi: 10.1097/MD.0000000000002710
Research Article: Clinical Case Report

Donohue syndrome ([DS]; leprechaunism) describes a genetic autosomal recessive disorder that results from the presence of homozygous or compound heterozygous mutations in the insulin receptor gene (INSR; 19p13.3–p13.2).

Donohue syndrome is associated with a fatal congenital form of dwarfism with features of intrauterine and postnatal growth retardation, exaggerated hyperglycemia with hyperinsulinism and dysmorphic abnormalities.

We present a case of DS owing to the rarity of this syndrome (1 case in every million births). We discuss how the disease presents, its genetic underpinning, and its prevention.

The case was encountered in an Arab male born on 1 September, 2014, for consanguineous parents. The delivery was via cesarean section at 37 weeks gestation due to severe intrauterine growth restriction and nonprogress labor term. The patient was admitted to the Neonatal Intensive Care Unit due to infection, and jaundice. Dysmorphic features, abnormalities of the craniofacial region, low birth weight, skin abnormalities, abdominal distension and hypertrichosis were observed. Laboratory examinations showed, hyperinsulinism, increased C-peptide, thrombocytopenia, leucopenia, and anemia.

The diagnosis of DS was done based on the combinations of typical dysmorphic characteristics, clinical evaluation, supported by genetic analysis and exaggerated biochemical results. Genetic diagnosis of DS was performed through analysis of DNA via polymerase chain reaction (PCR). A qualitative real-time PCR was used, to monitor the amplification of a targeted DNA molecule during the PCR. Other technique using sequencing of the INSR gene, which permits genetic diagnosis, counseling, and antenatal diagnoses in subsequent pregnancies, were also performed.

Treatment of DS is supportive and requires the combined efforts of a multidisciplinary team, which include pediatricians, endocrinologists, dermatologists, and other health care professionals. Currently, treatment with recombinant insulin-like growth factor 1 demonstrates effectiveness, and a combination treatment with insulin-like growth factor binding protein 3 resulted in an increased lifespan.

There is a scarcity of genetic information on DS among the Arab population. Consanguinity is one of underlying reasons for the appearance of rare genetic disorders. Inbreeding has long been considered a controversial phenomenon. Genetic counseling and overwhelming the alertness of the negative consequences of consanguinity on public health are warranted.

From the Pediatric and Neonatal Department, EMMS Nazareth—The Nazareth Hospital, Galilee Medical School—Bar-Ilan University (YN); Orthopedic Medicine, Medical Consulting Center, Nazareth Towers, General Medical Services “Sheruti Briut Clalit,” Galilee Medical School—Bar-Ilan University (YA); Pediatric and Neonatal Department, EMMS Nazareth—The Nazareth Hospital, Galilee Medical School, Galilee Medical School—Bar-Ilan University (AA); and Clinical Neuroscience, Neuropsychopharmacology & Population Genetics, Research Center, EMMS Hospital, Nazareth—The Nazareth Hospital (AB), Israel.

Correspondence: Abdalla Bowirrat, Professor of Clinical Neuroscience, Neuropsychopharmacology & Population Genetics, EMMS Hospital, Nazareth—The Nazareth Hospital, Israel (e-mail: bowirrat@gmail.com;bowirrat@netvision.net.il).

Abbreviations: DS = Donohue syndrome, INSR = Insulin receptor gene, IUGR = intrauterine growth restriction, NICU = Neonatal Intensive Care Unit, qPCR = Qualitative real-time Polymerase chain reaction, rh-IGF1 = Human insulin-like growth factor 1, RMS = Rabson Mendenhall syndrome.

Consent Form: Written informed consent was obtained from the patient's parents on behalf of the child for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.

The authors have no conflicts of interest to disclose.

This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0

Received November 12, 2015

Received in revised form January 13, 2016

Accepted January 14, 2016

Back to Top | Article Outline

INTRODUCTION

The most common forms of diabetes mellitus are due to insulin resistance, for example, a reduced or weak response to the effects of insulin beyond its receptor. Cases of diabetes due to an impaired insulin receptor or an absent insulin receptor are rare. Here we describe a case of leprechunism, a genetic disorder secondary to congenital lack of the insulin receptor. Owing to the rarity of this condition, its unique genetic underpinnings, and the role of consanguinity and cultural norms that lead to the risk for such a disorder to occur, we present a case and discuss its implications.

Back to Top | Article Outline

CASE REPORT

We report a case study of a 4-month-old male child of healthy, consanguineous parents living in urban environment after receiving full informed consent of the parents. The child was born on September 1, 2014 to a 26-year-old healthy mother at EMMS Nazareth Hospital. The delivery was via cesarean section at 37 weeks gestation due to severe intrauterine growth restriction and nonprogress labor term.

Apgar score at 1 minute after birth was 9, and at 5 minutes after birth was 10. Birth weight was 1290gr, head circumference was 31.3 cm, length = 36.3 cm, pulse = 138, breathing rate = 67/minute, blood pressure: systolic = 64, diastolic = 21, and blood saturation = 96.

The newborn was admitted to the Neonatal Intensive Care Unit (NICU) at the age of 1 day due to severe asymmetric IUGR, suspected infection with fever, and observed jaundice. He received immediately oxygen enrichment and antibiotic injection. During his admission at the NICU, various laboratory examinations were conducted including CBC, electrolytes, biochemistry, and several blood cultures. The laboratory findings revealed the following results: Hyperinsulinism (5560.4 pmol/L), neonatal hypoglycemia (24 mg/dL) and hyperglycemia (170 mg/dL), hypocholesterolemia (50 mg/dL), hypotriglyceridemia (36 mg/dL), cholestatic jaundice (direct bilirubin = 4.6 mg/dL; indirect bilirubin = 6.5 mg/dL), level of C-Peptide (2747 pmol/L), hypokalemia (2.8 mEq/L), neonatal thrombocytopenia (as low as 38,000/microL), leucopenia (as low as 2990/microL) and anemia of prematurity. Further investigations showed Urosepsis due to Enterobacter, right sided hydronephrosis and Hydrocele.

Clinical examinations for whole body systems were performed: chest X-Rays, cranial ultrasound, and heart echocardiogram which were all intact. Moreover, neurological examination was normal: the plantar grasp reflex, Moro reflex, and sucking reflex.

Dysmorphic features of the child were extremely abnormal, showing the following characteristics: Emaciation, lipoatrophy, genitomegaly and other distinctive characteristics including abnormalities of the craniofacial region with elfin facies, low birth weight and skin abnormalities, abdominal distension, hypertrichosis, and large low-set ears were observed clearly.

On the light of these findings, treatment was given which included: packed cells transfusion, platelet transfusion, antibiotic injections, and recombinant human insulin-like growth factor 1 (rh-IGF1) treatment was started because of poor weight gain. Several days after his admission the child's condition stabilized and he was discharged from the hospital with the recommendation of follow up in outpatient clinic.

Meanwhile, on the basis of typical dysmorphic characteristics and laboratory findings especially the exaggerated hyperinsulinaemia, we suspected Donohue syndrome ([DS]; leprechaunism; OMIM 246200) (Figure 1), which is the most severe form of inherited insulin-resistance disorders. In our case, it is worth to mention that the patient was a result of consanguineous mating and the fact that in the majority of previous cases of DS are results of consanguineous mating, strengthen our suspicion of DS.1

FIGURE 1

FIGURE 1

Therefore, DNA analysis of the child and his parents was examined. After a couple of weeks, we received the following genetic findings: both parents were carriers of a heterozygous deletion encompassing exon 14 of the insulin receptor gene (INSR) gene (Figure 2). Homozygous mutations in the INSR affect the region encoding the tyrosine kinase domain or affect the insulin-binding domain of the receptor. A qualitative real-time PCR was used, which is basically real-time polymerase chain reaction that is a laboratory technique of molecular biology based on the polymerase chain reaction (PCR). This technique monitors the amplification of a targeted DNA molecule during the PCR, that is, in real-time, and not at its end, as in conventional PCR. Real-time PCR can be used quantitatively—quantitative real-time PCR (as in our case) or semiquantitatively. Furthermore, the result of the child's genetic analysis was a homozygous deletion of exon 14 on the INSR gene after conducting sequencing analysis. The genetic results beside the dysmorphic characteristics and laboratory findings confirm the diagnosis of DS in this child.

FIGURE 2

FIGURE 2

After 4 months of continuous follow-up in outpatient clinic and hospitalizations the patient arrived to our NICU in a critical condition presenting the following symptoms: paleness, tachycardia, high fever (39.6°C), and distended abdomen. Sepsis was suspected and immediate antibiotic treatment was administered. Day later, the patient's condition deteriorated notably and signs of bradicardia and eventually cardiac arrest appeared due to septicaemia. All efforts to resuscitate the patient were in van and death was confirmed at 30/12/2014.

Back to Top | Article Outline

DISCUSSION

Donohue syndrome (OMIM 246200) is a genetic autosomal recessive disorder which results from the presence of homozygous or compound heterozygous mutations in the INSR (19p13.3–p13.2), that produce a total or near-total absence of functional insulin receptors.2–4

In 1948, Donohue5 first identified the physical and clinical findings of unusual craniofacial features, hirsutism, and various endocrine disturbances in a newborn female who was born to consanguineous parents. Six years later, a second sibling was born to the same consanguineous couple who had the same dysmorphic phenotype. Interest in this syndrome was aroused after the descriptive term “Leprechaunism” was suggested by the author.5

The characteristics of DS encompass a variety of distinguishing physical features and metabolic symptoms, such as severe intrauterine and postnatal growth retardation, multiple endocrine dysfunctions, hypertrichosis, virilization, emaciation, acanthosis nigricans, lipoatrophy, genitomegaly, postprandial hyperglycemia, fasting hypoglycemia, insulin resistance, hyperinsulinemia, and eventual development of ketoacidosis. Affected infants may also have distinctive characteristics, including abnormalities of the craniofacial region with elfin facies, low birth weight and skin abnormalities, and large low-set ears. It is worth to mention that many of the symptoms associated with DS differ in their severity and variation in expression from patient-to-patient might occur.6,7

Donohue syndrome is an extremely rare and fatal congenital form of dwarfism with less than 1 case in every million births. In reported cases, DS has occurred twice as often in females as in males (F2:M1).8

Donohue syndrome caused by mutations in the INSR resulting in either defects in insulin binding domain or receptor autophosphorylation and tyrosine kinase activity.9–11 Mutations in the INSR gene cause several inherited insulin-resistance disorders with paradoxical hypoglycaemia, which range from mild to severe. The syndromes of inherited insulin resistance actually form a wide clinical variety and many of these disorders are associated with diverse endocrine, metabolic, and genetic conditions and may reveal distinct phenotypic features.12

The human insulin receptor (INSR) (also known as CD220) is a transmembrane heterotetramer membrane glycoprotein receptor composed of 2 extracellular alpha subunits that bind insulin and 2 beta subunits that span the plasma membrane and have an intracellular tyrosine kinase domain, that is activated by insulin, thus a cascade of events is initiated, encompassing autophosphorylation, phosphorylation of cellular protein substrates, glucose transport, and glycogen synthesis. The alpha and beta subunits are encoded by a single INSR gene found on the short arm of chromosome 19, locus p13.3 to p13.2. The gene spans >120 kilobase pairs (kbp) and has 22 exons. All introns break off protein-coding segment of the gene. The 11 exons (exons 1–11) encoding the α subunits of the receptor are dispersed over >90 kbp, whereas the 11 exons (exons 12–22) encoding the β subunits are located together in a region of approximately 30 kbp.13,14

CD220 plays a crucial role in the regulation of glucose homeostasis, cell growth, differentiation, and apoptosis- functional processes that under degenerate environment may cause a plethora of clinical manifestations, such as diabetes mellitus and cancer.13,14

The isolation and characterization of cDNA clones encoding the human insulin receptor indicate that the α and β subunits of the insulin receptor are derived by proteolytic processing of a common 1382 amino acid preproreceptor.13,14

The diagnosis of DS depends on the combinations of typical dysmorphic characteristics, clinical evaluation, supported by biochemical results of exaggerated hyperinsulinaemia (usually >1000 pmol/l and sometimes in excess of 50,000 pmol/l) and genetic analysis. Prenatal diagnosis can be done through analysis of DNA obtain via amniocentesis. DNA collected from amniotic cells is analyzed via polymerase chain reaction (PCR). In DS, PCR is used to identify mutations to the insulin receptor gene. A qualitative real-time PCR is usually used, which is basically real-time polymerase chain reaction that is a laboratory technique of molecular biology based on the PCR. This technique monitors the amplification of a targeted DNA molecule during the PCR, that is, in real-time, and not at its end, as in conventional PCR. Real-time PCR can be used quantitatively—Quantitative real-time PCR (as in our case) or semiquantitatively. Sequencing of the INSR gene, now available on either a research or diagnostic basis in the United Kingdom,5,6,15 permits genetic diagnosis, counseling, and antenatal diagnosis in subsequent pregnancies.

Differential diagnosis of these disorders that share mutations in the INSR gene, include type-A insulin resistance syndrome, Rabson Mendenhall syndrome and DS. These disorders represent a continuum or spectrum of diseases. Rabson Mendenhall syndrome is considered a moderate form in severity between DS (which is fatal before age 2) and type-A insulin resistance syndrome (which is often not diagnosed until adolescence).15

Plethora of researches was conducted in hopes to find adequate treatment or intervention strategic plans for this rare condition. The treatment of DS is directed according to the specific symptoms that are apparent in each patient and requires the combined efforts of a team of specialists, which include pediatricians, endocrinologists, dermatologists, and other health care professionals.

In fact, treatment of DS is mainly supportive and aims to stabilize the symptoms. For instance, blood glucose levels must be maintained as constantly as possible with the use of frequent or continuous feeds and complex carbohydrates. Furthermore, treatment with recombinant insulin-like growth factor 1 may be considered. A combination treatment with insulin-like growth factor binding protein 3 resulted in an increased lifespan.16–19

The prognosis of this devastating disorder is complicated and fatal—whereas the disease onset itself in the prenatal life, usually within the seventh month of gestation; most Donohue Syndrome babies are either aborted or die within the first year of life.19

In this study we report a typical case of DS encountered in a 4-month-old child characterized by noticeable phenotypic abnormalities, distinguishing physical features, dysmorphic abnormalities and metabolic symptoms, such as: severe intrauterine and postnatal growth retardation and multiple endocrine dysfunctions. He also fulfilled the biochemical criteria of postprandial hyperglycemia, fasting hypoglycemia, insulin resistance, and hyperinsulinemiain.

Reviewing the literature of INSR mutations that are underpinning DS syndrome, over 130 different variations were identified. The majority of these variations were missense and nonsense mutations.15,1

The underpinning reasons for the manifestation of the typical phenotypic features especially the endocrine disturbances in DS (hirsutism and hypertrichosis)—encountered also in our patient and usually observed in almost all cases of DS—might be explained by the reduction of sex hormone-binding globulin provoked by insulin action via the type 1 insulin-like growth factor (1 IGF) receptor, which has functional and structural similarities with the insulin receptor.20

Type 1 IGF receptors mainly exist during fatal and early postnatal period and their productions from the liver adipocyte cells wither away and disappear during adulthood. As a result of the plummeting activity of sex hormone-binding globulin by insulin action via the type (1 IGF) receptor, augmentation levels of the free circulating androgen (hyperandrogenism) are observed causing the endocrine disturbances in DS regardless of moderately high level of androstenedione, intact level of testosterone and feeble activity of androgens.21–23

In addition, many studies demonstrate that IGF-1 acts as autonomous growth hormone and plays important role in body development and have great manipulations on intrauterine linear growth and development.24–26

The action of IGF-1 as an essential growth hormone, stimulating linear growth and has self-regulating growth-stimulating effect already at delivery, and throughout babyhood, was proven owing to its deficiency and through the observation of skeleton underdevelopment, as is the case of other organ growth.27,28

Indeed, various developmental abnormalities are encountered, including many body organs, such as; heart, brain, weakness and deficit of the body musculature, loss of muscle strength and maturation, facial bones deformities, dwarfism and short extremities as a result of the failure to generate IGF-1.29–33

In this unique study, we are stressing the importance of the preventive medicine in rein in the inbreeding mating tradition especially in Mediterranean basin areas, where this phenomenon prevails.

Indeed, our patient was born to first cousin parents from the Arab community in Nazareth, whereas there is a paucity of genetic information on DS. Consanguineous mating is a unique form of union, which may lead to genetic detrimental effects as a consequence of homozygosity of harmful genes. The increased frequency of homozygous genotypes allowed the less common alleles to become manifested homozygous,34 thus descendants of consanguineous parents have higher susceptibility to congenital malformation35,36 neonatal, postneonatal, and infant mortality than those of unrelated parents.37–41

Due to homozygosity of recessive alleles as a result of inbreeding, numerous deleterious alleles appeared in the genome, since the majority of genetic disorders originate from a recessive genotype.42–46

The growing propensity for such rare recessive inheritance diseases to appear is triggered by consanguineous marriages, which lead to increased genetic homogeneity of inbred individuals, due to similarities between contributing paternal and maternal genetic material.

Historically, since the discovery of the first case by Donohue (1948) to date, the majority of cases encountered in the literature were a result of interbreeding mating (Figure 3), which strengthens the hypothesis that consanguinity is an underlying cornerstone reason for the appearance of these rare genetic disorders.24,27,47–54

FIGURE 3

FIGURE 3

In our DS case study, the parents are first cousins, and the genetic analysis confirms that they are carriers of a similar mutant allele inherited from a common ancestor. In addition to this, the fact that DS is an uncommon disease and does not occur at high rate in the Arab community suggests that consanguineous mating is a strong trigger for the appearance of such mutations.

Indeed, consanguineous marriage is a particular form of assortative mating, which is deeply seated and deeply rooted in many communities globally; and especially in Mediterranean region.55 It is estimated that worldwide over 20% of the human population live in communities with a preference for consanguineous marriage, and over 8.5% of all children have consanguineous parents.

Back to Top | Article Outline

CONCLUSIONS

There is a scarcity of genetic information on DS among the Arab population. Intermarriages are usually socially motivated but can be genetically harmful. The study and consequences of inbreeding are of considerable concerns in the field of genetics.4 2Due to the harmful consequences of consanguineous mating; this public health phenomenon should be dissuaded and actively discouraged. However, preventive strategy should explain the detrimental consequences of this type of mating. Genetic counseling is extremely recommended and should be a mandatory demand prior to marriage decision. Families at risk should be dissuaded and actively discouraged to have children.

Back to Top | Article Outline

Acknowledgments

We thank Aia Bowirrat for her contribution in revising and editing the study. We confirm that Aia Bowirrat gives her permission to be named.

Back to Top | Article Outline

REFERENCES

1. Ruddy SSK, Kahn CR. Epidermal growth factor receptor defects in leprechaunism: a multiple growth factor-resistant syndrome. J Clin Invest 1989; 84:1569–1576.
2. Taylor SI, Arioglu E. Genetically defined forms of diabetes in children. JCEM 1999; 84:4390–4396.
3. Unal S, Aycan Z, Halsall DJ, et al. Donohue syndrome in a neonate with homozygous deletion of exon 3 of the insulin receptor gene. J Pediatr Endocrinol Metab 2009; 22:669–674.
4. Longo N, Wang Y, Smith SA, et al. Genotypephenotype correlation in inherited severe insulin resistance. Hum Mol Genet 2002; 11:1465–1475.
5. Donohue WL. Clinical Conference: dysendocrinism. J Pediatr 1948; 32:739–1739.
6. Longo N, Langley SD, Griffin LD, et al. Two mutations in the insulin receptor gene of a patient with leprechaunism: application to prenatal diagnosis. JCEM 1995; 80:1496–1501.
7. Semple RK, Savage DB, Halsall DJ. Weiss RE, Refetoff S, et al. Syndromes of severe insulin resistance and/or lipodystrophy. Genetic Diagnosis of Endocrine Disorders. London: Elsevier; 2010. 39–52.
8. Kosztolanyi G. Leprechaunism/Donohue syndrome/insulin receptor gene mutations: a syndrome delineation story from clinicopathological description to molecular understanding. Eur J Pediatr 1997; 156:253–255.
9. Grasso V, Colombo C, Favalli V, et al. Six cases with severe insulin resistance (SIR) associated with mutations of insulin receptor: is a Bartter-like syndrome a feature of congenital SIR? Acta Diabetol 2013; 50:951–957.
10. Rojek A, Niedziela M. Insulin receptor defect as a cause of Rabson-Mendenhall syndrome and other rare genetic insulin resistance syndromes. Pediatr Endocrinol Diabetes Metab 2010; 16:205–212.
11. Park JW, Kuehn HS, Kim SY, et al. Down regulation of Wnt-mediated ROS generation is causally implicated in leprechaunism. Mol Cells 2010; 29:63–69.
12. Semple RK, Savage DB, Cochran EK, et al. Genetic syndromes of severe insulin resistance. Endocrine Reviews 2011; 32:498–514.
13. Seino S, Seino M, Nishi S, et al. Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci 1989; 86:114–118.
14. Ebina Y, Ellis L, Jarnagin K, et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signaling. Cell 1985; 40:747–758.
15. Ardon O, Procter M, Tvrdik T, et al. Sequencing analysis of insulin receptor defects and detection of two novel mutations in INSR gene. Mol Genet Metab Rep 2014; 1:71–84.
16. Odeh R, Alassaf A, Al-Qudah A. Donohue syndrome: a new case with a new complication. J Pediatr Endocrinol Metab 2015; 28:951–954.
17. Walenkamp MJE, Wit JM. Genetic disorders in the GH–IGF-I axis in mouse and man. Eur J Endocrinol 2007; 157:S15–S26.
18. Nakae J, Kato M, Murashita M, et al. Long-term effect of recombinant human insulin-like growth factor i on metabolic and growth control in a patient with leprechaunism. JCEM 1998; 83:542–549.
19. Kato M. Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes. Hokkaido Igaku Zasshi 1998; 73:613–625.
20. De Meyts P, Wallach B, Christoffersen C, et al. The insulin-like growth factor-1 receptor. Structure, ligand binding mechanism and signal transduction. Horm Res 1994; 42:152–169.
21. Kasuga M, Van Obberghen E, Nissley SP, et al. Demonstration of two subtypes of insulin-like growth factor receptors by affinity cross-linking. J Biol Chem 1981; 256:5305–5308.
22. Chernausek SD, Beach DC, Banach W, et al. Characteristics of hepatic receptors for somatomedin C-/insulin-like growth factor I and insulin in the developing human. J Clin Endocrinol Metab 1987; 64:737–743.
23. Ogilvey-stuart AL, Soos MA, Hands SJ, et al. Hypoglycemia and resistance to ketoacidosis in a subject without functional insulin receptors. J Clin Endocrinol Metab 2001; 86:3319–3326.
24. Lakatos I, Kallo A, Szijarto L. Leprechaunism (Donohue syndrome). Orv Hetil 1963; 104:1075–1080.
25. Laron Z. Frick P, Von Harnack GA, Kochsiek GA, et al. Laron type dwarfism (hereditary somatomedin deficiency): a review. Advances in Internal Medicine and Pediatrics. Berlin-Heidelberg: Springer-Verlag; 1984. 117–150.
26. Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol 2001; 54:311–316.
27. Psiachou H, Mitton S, Alaghband-Zadeh J, et al. Leprechaunism and homozygous nonsense mutation in the insulin receptor gene. Lancet 1993; 342:924.
28. Feinberg MS, Scheinowitz M, Laron Z. Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome). Am J Cardiol 2000; 85:209–213.
29. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism? Isr J Med Sci 1966; 2:153–155.
30. Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 1968; 4:883–894.
31. Brat O, Ziv I, Klinger B, et al. Muscle force and endurance in untreated and human growth hormone or insulin-like growth factor-I-treated patients with growth hormone deficiency or Laron syndrome. Horm Res 1997; 47:45–48.
32. Lurie R, Ben-Amitai D, Laron Z. Impaired hair growth and structural defects in patients with Laron syndrome (primary IGF-I deficiency). Horm Res 2001.
33. Gluckman PD, Gunn AJ, Wray A, et al. Congenital idiopathic growth hormone deficiency associated with prenatal and early postnatal growth failure. J Pediatr 1992; 121:920–923.
34. Weber DR, Stanescu DE, Semple R, et al. Continuous subcutaneous IGF-1 therapy via insulin pump in a patient with Donohue syndrome. J Pediatr Endocrinol Metab 2014; 27:1237–1241.
35. Mohamed S. An infant with Leprechaunism, ambiguous genitalia and poor glycemic control: A management challenge. Acta Endocrinol 2014; 10:134–139.
36. Mokhtar MM, Abdel-Fattah MM. Consanguinity and advanced maternal age as risk factors for reproductive losses in Alexandria, Egypt. Eur J Epidemiol 2001; 17:559–565.
37. Kushki AM, Zeyghami B. The effect of consanguineous marriages on congenital malformation. J Res Med Sci 2005; 10:298–301.
38. Bromiker R, Baruch M. Association of parental consanguinity with congenital malformations among Arab newborns in Jerusalem. Clin Genet 2004; 66:63–66.
39. Sawardekar KP. Genetic analysis of lethal congenital malformations causing perinatal mortality at Nizwa Hospital, Oman. Clin Genet 2004; 66:239–243.
40. Bittles AH, Grant JC, Shami SA. Consanguinity as a determinant of reproductive behaviour and mortality in Pakistan. Int J Epidemiol 1992; 22:463–467.
41. Grant JC, Bittles AH. The comparative role of consanguinity in infant and childhood mortality in Pakistan. Ann Hum Genet 1997; 61:143–149.
42. Stoltenberg C, Magnus P, Skrondal A, et al. Consanguinity and recurrence risk of stillbirth and infant death. Am J Public Health 1999; 89:517–523.
43. Jorde LB. Consanguinity and prereproductive mortality in the Utah Mormon population. Hum Hered 2001; 52:61–65.
44. Jimenez-Sanchez G, Childs B, Valle D. Human disease genes. Nature 2001; 409:853–855.
45. Brown WM, Beck SR, Lange EM, et al. Framingham Heart Study: age-stratified heritability estimation in the Framingham Heart Study families. BMC Genet 2003; 4:S32.
46. Lander ES, Botstein D. Homozygosity mapping: a way to map human recessive traits with the DNA of inbred children. Science 1987; 236:1567–1570.
47. Wright AF, Teague PW, Bruford E. Edwards JH, Pawlowitzki IH, Thompson E, et al. Problems in dealing with linkage heterogeneity in autosomal recessive forms of retinitis pigmentosa. Genetic Mapping of Disease Genes. UK: Academic Press; 1997. 255–272.
48. Broman KW, Weber JL. Long homozygous chromosomal segments in reference families from the Centre d’Étude du Polymorphisme Humain. Am J Hum Genet 1999; 65:1493–1500.
49. Al-Gazali LI, Khalil M, Devadas K. A syndrome of insulin resistance resembling leprechaunism in five sibs of consanguineous parents. J Med Genet 1993; 30:470–475.
50. Dyduch A, Karczewska K, Bubala H, et al. Leprechaunism (Donohue syndrome) in infants. Pediatr Pol 1982; 57:429–436.
51. Donohue WL, Uchida I. Leprechaunism: a euphemism for a rare familial disorder. J Pediatr 1954; 45:505–519.
52. Koklu E, Ariguloglu EA, Koklu S. Leprechaunism (Donohue syndrome): report of a case in a newborn. JPEM 2014; 27:207–208.
53. Dekaban AS. Metabolic and chromosomal studies in leprechaunism. Arch Dis Child 1965; 40:632–636.
54. Der Kaloustian VM, Kronfol NM, Takla RJ, et al. Leprechaunism: a report of two new cases. Am J Dis Child 1971; 122:442–445.
55. Bowirrat A, Armaly Z. Consanguineous marriages in the Middle East: nature versus nurture. Open Complement Med J 2013; 5:1–10.
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.